Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3127c0ebee3f865b211b019fac84286 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb9c6b40161bafe7bd55f0b4defcea04 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-999 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33 |
filingDate |
2015-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3d340bc9491037ec7d86d94ef07d5bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d1da98687f2c9234efef7e20e8966f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8914e05b3cd840c3c05af6bd5c8f2549 |
publicationDate |
2017-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3226898-A1 |
titleOfInvention |
Bromodomain inhibitor as adjuvant in cancer immunotherapy |
abstract |
Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule PDL1, and to be capable of restoring the responsiveness of tolerant T-cells. Therefore, disclosed is a method for promoting T-cell activation during cancer immunotherapy in a subject that involves administering to a subject undergoing cancer immunotherapy a composition comprising a bromodomain inhibitor. Also disclosed is a method for treating cancer in a subject, comprising co-administering to the subject a bromodomain inhibitor and an immunostimulatory agent. |
priorityDate |
2014-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |